Public market insider selling at Profound Medical (PRN)

Public market insider selling at Profound Medical (T:PRN)

Aaron Davidson, CFO, disposed of 31,644 Common Shares on a direct ownership basis at a price of $28.000 on March 5th, 2021. The insider also disposed of 6,250 Common Shares on a direct ownership basis at a price of US$22.000 on March 5th, 2021. This represents a $1,060,217 divestment of the company's shares and an account share holdings change of -100.0%.

Profound Medical is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company's products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.